Clinical Trials Logo

Filter by:
NCT ID: NCT00739154 Not yet recruiting - Clinical trials for Primary Open Angle Glaucoma

Protective Effect of Phenytoin on Glaucoma

Start date: November 2008
Phase: N/A
Study type: Observational

since glaucoma is considered an optic neuropathy, new treatments for glaucoma are being continuously investigated, including neuroprotection. Previous studies implied that phenytoin, a potent anti-convulsive drug, has a neuroprotective role, and Na+ channels blockage was suggested as a possible mechanism. This study predicts that glaucoma patients taking Phenytoin will have a less advanced glaucoma as compared to patients not taking the drug. Glaucoma severity will be determined by visual acuity, visual fields, optic disc cupping and nerve fiber layer thickness

NCT ID: NCT00739128 Terminated - Celiac Disease Clinical Trials

Response to Hepatitis B Vaccine in Celiac Disease Patients

Start date: February 2009
Phase: N/A
Study type: Interventional

Celiac disease and infection with hepatitis B virus (HBV) are very prevalent worldwide and carry a high morbidity rate. It has been recently shown that patients with celiac disease very often fail to develop immunity after standard vaccination for HBV during infancy. In this study, we will evaluate whether a second vaccination series via a different route of administration (into the skin rather than the muscle) results in a better immunological response in celiac patients. Eligible patients will be randomized to receive a 3-dose vaccination series into the skin or to the muscle. Rate of responders and level of immunity will be compared. This study will facilitate better protection of celiac patients to this potentially deadly virus.

NCT ID: NCT00738530 Completed - Renal Cell Cancer Clinical Trials

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

Start date: June 2004
Phase: Phase 3
Study type: Interventional

This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in patients with metastatic renal cell cancer (clear cell type) who have had nephrectomy. The anticipated time of study treatment is 1-2 years, and the target sample size is 500+ individuals.

NCT ID: NCT00738075 Not yet recruiting - Parkinson's Disease Clinical Trials

Automatic Recognition of Freezing of Gait Episodes

Start date: October 2008
Phase: N/A
Study type: Observational

The investigators hypothesize that mathematical algorithm can identify freezing episodes based on data obtained from accelerometer.

NCT ID: NCT00737932 Completed - Crohn's Disease Clinical Trials

Laquinimod Phase IIa Study in Active Crohn's Disease

Start date: May 2010
Phase: Phase 2
Study type: Interventional

The study aims to evaluate the safety and clinical effect of daily oral treatment of Laquinimod capsules in active moderate to severe Crohn's disease. This study will assess Laquinimod doses of 0.5mg /day to 2 mg/day in sequential dose groups (cohorts). Laquinimod is a novel immunomodulating drug which is currently in advanced stages of development by Teva Pharmaceuticals Ltd. for Multiple Sclerosis.

NCT ID: NCT00737659 Recruiting - Renal Transplant Clinical Trials

CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients

MMF
Start date: August 2008
Phase: Phase 4
Study type: Interventional

In order to avoid renal transplant rejection, the immune system should be suppressed. After the renal transplant subjects are treated with a combination of two to four different types of immunosuppressive drugs. Theses drugs are very efficient in the prevention of the renal transplant rejection. Still, they can cause side effect. Research in renal transplant tries to find the best treatment in order to avoid renal rejection on one hand and to reduce as much as possible the undesired adverse and toxicity effects on the other hand. Therapeutic efficacy and the onset of adverse effects are influenced by levels of mycophenolic acid (MPA, the active metabolite of MMF, CellCept®). The primary objective of this study is to assess the treatment superiority of CellCept® Dose Adjustment treatment, based on individual MPA concentration value monitored periodically, against treatment with CellCept® Fixed Dose (standard care).

NCT ID: NCT00737620 Completed - Clinical trials for Hemodialysis Fistula Thrombosis

Evaluation of Heparin Bonded Vascular Graft Versus Standard Graft in Prosthetic Arteriovenous Access for Hemodialysis

Start date: March 2008
Phase: Phase 4
Study type: Interventional

The majority of bridge graft fistula with polytetrafluoroethylene (PTFE) for hemodialysis access will develop stenosis at the venous anastomosis and eventually will fail. Aspirin have been used for many years as a prophylactic drug therapy to prevent thrombosis but good clinical evidence for its benefit is lacking. Many drugs have been used to reduce intimal hyperplasia in animal models. Until recently there has been little success in clinical trials of anti-inflammatory, antiproliferative, antiplatelet, antithrombotic or calcium channel blocking drugs. Recently a major breakthrough was done by GORE when introducing the new heparin bonded PTFE graft by covalent attachment. This trial is planed to assess and compare between the GORE-TEX® PROPATEN vascular graft versus unmodified ePTFE grafts the patency and complication.

NCT ID: NCT00737542 Unknown status - Pain Clinical Trials

Local Lidocaine Infiltration for Pain Management Post Cesarean Delivery.

Start date: n/a
Phase: N/A
Study type: Interventional

The objective of this prospective, double-blinded, placebo-controlled, randomized study is to evaluate the impact of preemptive analgesia using incisional site infiltration of lidocaine as compared to saline solution on post operative pain control in women undergoing cesarean deliveries.

NCT ID: NCT00737529 Completed - Clinical trials for Mantle Cell Lymphoma

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

EMERGE
Start date: December 22, 2008
Phase: Phase 2
Study type: Interventional

To evaluate the safety and efficacy of Lenalidomide (Revlimid (R)) in subjects with mantle cell lymphoma who have relapsed, progressed or are refractory to bortezomib.

NCT ID: NCT00737425 Recruiting - Wounds Clinical Trials

Safety and Efficacy Study of Pain Shield Device to Treat Subjects Following Laparoscopic-Assisted Abdominal Surgery

Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate safety and efficacy of PainShield device, based on ultrasound technology, for postoperative pain relief and wound healing following a laparoscopic-assisted abdominal surgery.